Sequence-Specific Cleavage of HIV mRNA by a Ribozyme Mimic

Bashkin, James K.; Frolova, Elena I.; Sampath, UmaShanker

doi:10.1021/ja00092a064

Cited by 149 publications

(103 citation statements)

References 1 publication

Supporting

Mentioning

102

Contrasting

Order By: Relevance

“…and expression of the BLV core protein p24 was decreased by >60%. It can be pre dicted that the application of ex vivo chemically synthesized hammerhead RZs will allow greater access to their HIV target since they are not prey to the pitfalls of RZ gene transfection strategies, namely, insufficient intracellular expression and in adequate gene transfer [44,45].…”

Section: Ribozymes In Retroviral Diseasementioning

confidence: 99%

Ribozymes: Possible New Tools for Treatment of Cancer and Retroviral Diseases?

Kiehntopf¹,

Brach²,

Herrmann³

1995

Oncol Res Treat

View full text Add to dashboard Cite

Ribozymes represent an exciting new class of sophisticated antisense molecules as they combine the inherent substrate sequence specificity of complementary nucleic acids with the ability to catalytically degrade and, thus, inactivate susceptible substrate RNAs. This article reviews the biology and biochemistry of this remarkable class of molecules and discusses the implications for clinical medicine.

show abstract

Section: Ribozymes In Retroviral Diseasementioning

confidence: 99%

Ribozymes: Possible New Tools for Treatment of Cancer and Retroviral Diseases?

Kiehntopf¹,

Brach²,

Herrmann³

1995

Oncol Res Treat

View full text Add to dashboard Cite

show abstract

“…One approach involves attachment of the metal ion catalyst to a recognition agent that binds tightly to an RNA sequence or RNA structural motif and places the catalyst in close proximity to a specific phosphate diester. As an example, metal ion catalysts have been attached to antisense oligonucleotides as recognition agents [1,[4][5][6][7][8][9][10][11][12][13][14] to promote sequence-specific cleavage. Fewer examples are available of catalysts that cleave RNA based on recognition of a structural motif [15,16].…”

Section: Introductionmentioning

confidence: 99%

Cleavage of an RNA analog by Zn(II) macrocyclic catalysts appended with a methyl or an acridine group

Rossiter

Mathews

Morrow

2007

Journal of Inorganic Biochemistry

View full text Add to dashboard Cite

“…Thus, attachment of chemical entities to antisense oligonucleotides capable of hydrolyzing the phosphodiester backbone of RNA, allows the construction of so-called artificial chemical ribonucleases (ref. [13][14][15][16][17][18][19][20][21]. In particular, macrocyclic lanthanide complexes, such as in 3, in combination with modified antisense oligonucleotides, can be used to specifically cleave mRNA.…”

Section: Introductionmentioning

confidence: 99%

Development of artificial ribonucleases

Häner¹,

Hall²,

Pfützer³

et al. 1998

Pure and Applied Chemistry

View full text Add to dashboard Cite

Antisense oligonucleotides offer a new way of treating genetically based diseases by interfering with protein expression on the mRNA level. First generation phosphorothioate antisense oligonucleotides have shown promising results in animal experiments and several compounds are currently being tested in the clinics against a variety of diseases. Nevertheless, improvements of various aspects of the technology, such as stability, reduction of length and target affinity of oligonucleotides, are still highly desirable. As a consequence, a large number of chemical modifications of antisense compounds has been reported during the last decade. Unlike phosphorothioates, however, most second generation modifications do not induce degradation of messenger RNA by an RNase H-based mechanism, which is in most cases an essential component of antisense activity. An alternative approach to enable degradation of the mRNA comprises the covalent attachment of RNA cleaving groups to modified oligonucleotides. Macrocyclic lanthanide complexes, in combination with modified antisense oligonucleotides, can be used to specifically cleave mRNA. The preparation, properties and use of such artificial ribonucleases are highlighted. In particular, the design and preparation of constructs cleaving RNA with multiple turn-over is described.

show abstract

Sequence-Specific Cleavage of HIV mRNA by a Ribozyme Mimic

Cited by 149 publications

References 1 publication

Ribozymes: Possible New Tools for Treatment of Cancer and Retroviral Diseases?

Ribozymes: Possible New Tools for Treatment of Cancer and Retroviral Diseases?

Cleavage of an RNA analog by Zn(II) macrocyclic catalysts appended with a methyl or an acridine group

Development of artificial ribonucleases

Contact Info

Product

Resources

About